Diabetes is a chronic health condition affecting blood glucose levels. In some cases, it requires constant management in the form of monitoring blood glucose levels and administering insulin.

Insulet Corp. PODD recently announced that its Omnipod 5 Automated Insulin Delivery (“AID”) system is now available in France with Dexcom’s DXCM G6 sensor integration. Additionally, the company made ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod ® 5 App for iPhone is now compatible with the ...

Insulet Corp. PODD recently announced positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial. The landmark study assessed the impact of AID ...

ACTON, Mass., November 20, 2024--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products ...

Insulet Corporation PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. The stock carries a Zacks Rank #2 (Buy).